Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tachyplesin activates the classic complement pathway to kill tumor cells.

Jinguo Chen1, Xue-Ming Xu, Charles B Underhill

  • 1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA.

Cancer Research
|June 3, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of limaprost combined with unilateral biportal endoscopic surgery in the treatment of lumbar spinal stenosis: based on time effects and stratified analysis.

Frontiers in surgery·2026
Same author

<i>Ex vivo</i> bradykinin as a functional biomarker for angioedema with normal C1-inhibitor.

The journal of allergy and clinical immunology. Global·2026
Same author

Anesthetic management for orthognathic surgery under ERAS protocol: a narrative review.

Frontiers in oral health·2026
Same author

Stearoyl-CoA Desaturase (SCD) Gene Based Molecular Breeding Enhances Nutritional Quality and Growth Performance in the Oyster (Crassostrea angulata).

Marine biotechnology (New York, N.Y.)·2026
Same author

Microglial senescence and epigenetic reprogramming in alzheimer's disease: An immunometabolic perspective.

Experimental gerontology·2026
Same author

Multi-Scale Fourier Temporal Network for Multi-Source Precipitation Nowcasting.

Sensors (Basel, Switzerland)·2026

Tachyplesin peptide activates the complement cascade by binding to hyaluronan and C1q, leading to tumor cell death. This mechanism involves complement component C4 and C3 activation, damaging tumor cell membranes.

Area of Science:

  • Immunology
  • Biochemistry
  • Cell Biology

Background:

  • Tachyplesin, a cationic peptide, exhibits antitumor properties but its mechanism of action is poorly understood.
  • The complement system is a crucial part of innate immunity involved in pathogen clearance and inflammation.

Purpose of the Study:

  • To elucidate the mechanism by which tachyplesin exerts its antitumor effects.
  • To identify the molecular interactions underlying tachyplesin's activity.

Main Methods:

  • Phage display was used to identify proteins interacting with tachyplesin.
  • Enzyme-linked immunosorbent assay (ELISA) and affinity precipitation confirmed interactions.
  • Flow cytometry, Western blotting, and confocal microscopy assessed complement activation on tumor cells.

Related Experiment Videos

  • Functional assays measured membrane permeability and cell viability.

    • Main Results:

    • Tachyplesin interacts with the collagen-like domain of C1q and hyaluronan on tumor cells.
    • Tachyplesin activates the classical complement cascade, leading to C4 and C3 cleavage and C5b-9 formation.
    • Complement activation on tumor cells was blocked by hyaluronidase or excess hyaluronan.
    • Tachyplesin and serum treatment increased membrane permeability and induced tumor cell death, effects dependent on complement activity and hyaluronan.

    Conclusions:

    • Tachyplesin activates the classical complement cascade via binding to cell surface hyaluronan and serum C1q.
    • This activation leads to tumor cell membrane damage and subsequent cell death.
    • The findings reveal a novel mechanism for tachyplesin's antitumor activity involving the complement system.